It looks like there won’t be any Yelp reviews, color-coded drugs, or seasteading in the Food and Drug Administration’s future. Instead, President Donald Trump is going with the establishment candidate — and the biotech industry couldn’t be more relieved.
Dr. Scott Gottlieb, a former deputy commissioner at FDA who also has a Wall Street pedigree, is Trump’s nominee to lead the agency, ending months of speculation and consternation among biotech insiders.
May I observe that until Scott is formally designated as the nominee and the Senate approves him, it is too early to celebrate. While this potential choice counts as a pleasant surprise, the President always seems to have ‘another surprise’ in the wings. Senate confirmation first then pop the corks, assuming, of course, that now the nomination is set.
Comments are closed.